Abstract
The preproglucagon gene encodes, in addition to glucagon, two smaller peptides with structural similarity: glucagon-like peptides 1 and 2. Glucagon-like peptide 1 (GLP-1) 7–36 amide is the most powerful incretin candidate. In the present study, GLP-1 immunoreactivity was investigated in tissue specimens of various types of gastroenteropancreatic tumors, and the serum-levels of GLP-1 were assayed. Immunohistochemical staining of 88 tumors revealed GLP-1 immunoreactivity in 17 neoplasias (19.3 %), viz., in 7 out of 33 non-functioning tumors, 4 out of 20 gastrinomas, 4 out of 13 insulinomas, 1 out of 3 vasoactive-intestinal-polypeptide (VIP)omas and 1 adrenocorticotropic-hormone (ACTH)-producing tumor. In these tumors, GLP-1-immunoreactive cells were distributed either diffusely, arranged in clusters, or as single cells. All GLP-1-positive tumors were immunoreactive for glucagon or glicentin, 10 tumors were immunoreactive for pancreatic polypeptide, and 8 tumors for insulin. Ultrastructural analysis of 8 GLP-1-positive tumors, with the immunogold technique, demonstrated GLP-1 immunoreactivity mainly in cells resembling the A-cells of the pancreas or the L-cells of the gut. Of the 17 GLP-1-immunoreactive tumors, 15 were primarily located in the pancreas. Additionally, 2 non-functioning tumors of the rectum were GLP-1 immunoreactive. Five tumors were GLP-1 immunoreactive from 9 patients with multiple endocrine neoplasia I syndrome. Patients with GLP-1-immunoreactive tumors were characterized by a significantly lower rate of distant metastases (P<0.01) and a higher rate of curative resections (P<0.05). In 2 out of 22 patients, elevated serum-levels of GLP-1 were found: one patient with a vasoactive-intestinal-polypeptide (VIP)oma and 1 patient with a non-functioning tumor. This indicates that GLP-1 might be secreted at least by a few gastroenteropancreatic endocrine tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alpert S, Hanahan D, Teitelman G (1988) Hybrid insulin genes reveal a developmental lineage for pancreatic endocrine cells and imply a relationship with neurons. Cell 53:295–308
Becker SW, Kahn D, Rothman S (1942) Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syph 45:1069–1072
Bell GI, Santerre RF, Mullenbach GT (1983) Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302:716–718
Bendayan M, Zollinger M (1983) Ultrastructural localization of antigenic sites on osmium fixed tissues applying the protein-A gold technique. J Histochem Cytochem 31:101–109
Drucker DJ, Asa SL, Sieverberg J, Brubacher PC (1990) Molecular and cellular analysis of a neoplastic A cell tumor. Cancer 65:1762–1770
Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22:283–291
Fehmann HC, Göke B, Göke R, Trautmann ME, Arnold R (1989) Synergistic stimulatory effect of glucagon-like peptide 1 (7–36) amide and glucose-dependent insulin-releasing polypeptide on the endocrine rat pancreas. FEBS Lett 252:109–112
Fehmann HC, Göke R, Göke B (1992) Glucagon-like peptide-1 (7–37)/(7–36)amide is new incretin. Mol Cell Endocrinol 85:39–44
Fiocca R, Rindi G, Capella C, Grimelius L, Polak JM, Schwartz TW, Yanaihara N, Solcia E (1987) Glucagon, glicentin, proglucagon, PYY, PP and proPP-icosapeptide immunoreactivities of rectal carcinoid tumors and related non-tumor cells. Regul Pept 17:9–29
Garaud JC, Eloy R, Moody AJ, Stock C, Grenier JF (1980) Glucagon- and glicentin-immunoreactive cells in the human digestive tract. Cell Tissue Res 213:121–136
Göke R, Conlon JM (1988) Receptor for glucagon-like peptide-1 (7–36) amide on rat insulinoma-derived cells. J Endocrinol 126:357–362
Göke R, Wagner B, Fehmann HC, Göke B (1993) Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7–36) amide on the rat pancreas. Res Exp Med (Berl) 193:97–103
Goodland RA, Ghatei MA, Bloom SR, Wright NA (1991) Glucagon 1–21 reduces intestinal epithelial cell proliferation in parenterally fed rats. Exp Physiol 76:943–949
Gregor M, Riecken EO (1985) Production and characterization of N-terminally and C-terminally directed monoclonal antibodies against pancreatic glucagon. Gastroenterology 89:571–580
Gregor M, Stallmach A, Menge H, Riecken EO (1990) The role of gut-glucagon-like immunoreactants in the control of gastrointestinal epithelial cell renewal. Digestion 46[Suppl 2]:59–65
Hamid QA, Bishop AE, Sikri KL, Varndell IM, Bloom SR, Polak JM (1986) Immunocytochemical characterization of 10 pancreatic tumors, associated with the glucagonoma syndrome, using antibodies to separate regions of the pro-glucagon molecule and other neuroendocrine markers. Histopathology 10:119–133
Heinrich G, Gros P, Habener JF (1984) Glucagon gene sequence: four of six exons encode separate functional domains of rat pre-proglucagon. J Biol Chem 259:14082–14087
Hendriks T, Jansen JBJM, Van Tongeren JHM (1984) The glucagonoma syndrome: stimulus-induced plasma responses of circulating glucagon components IRG-9000 and IRG-3500. Acta Endocrinol (Copenh) 105:226–232
Holst JJ (1983) Molecular heterogeniety of glucagon in normal subjects and in patients with glucagon-producing tumors. Diabetologia 24:359–365
Holst JJ (1985) Glucagon-producing tumors. In: Cohen S, Soloway RD (eds) Hormone-producing tumors of the gastrointestinal tract. Contemporary issues in gastroenterology, vol 5. Churchill Livingstone, New York Edingburgh London pp 57–84
Holst JJ, Orskov C, Nielsen OV, Schwartz TW (1987) Truncated glucagon-like peptide-I, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169–174
Hsu S, Raine L, Fanger H (1981) Use of avidin-biotin-complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577–580
Komatsu R, Matsuyama T, Namba M, Watanabe M, Itho H, Kono N, Tarui S (1989) Glucagonostatic and insulinotropic action of glucagonlike peptide I (7–36)amide. Diabetes 38:902–905
Kreymann B, Ghatei MA, Williams G, Bloom SR (1987) Glucagon-like peptide 1 7–36: a physiological incretin in man. Lancet 2:1300–1302
Larsson LI, Grimelius L, Håkanson R, Rehfeld JF, Stadil F, Holst J, Angerval L, Sundler F (1975) Mixed endocrine pancreatic tumors producing several peptide hormones. Am J Pathol 79:271–279
Lund PK, Hoyt E, Simmons JG, Martin H (1993) Regulation of intestinal glucagon gene expression during adaptive growth of small intestine. First International Symposium on GLP-1, Copenhagen. Digestion 54 (in press)
Mallinson CN, Bloom SR, Warin AP, Salmon PR, Cox B (1974) A glucagonoma syndrome. Lancet 2:1–5
Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF (1986) Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880–11889
Mojsov S, Kopczynski MG, Habener JF (1990) Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 265:8001–8008
Nathan DM, Fogel H, Mojsov S, Habener JF (1990) Insulinotropic action of glucagon-like peptide-1, 7–37 (GLP-1(7–37)) in non-diabetic and NIDDM subjects. Diabetes Care 15:270–276
Novak U, Wilks A, Bell G, McEwen S (1987) Identical mRNA for preproglucagon in pancreas and gut. Eur J Biochem 164:553–558
Orskov C, Holst JJ, Poulsen SS, Kirkegaard P (1987) Pancreatic and intestinal processing of proglucagon in man. Diabetologica 30:874–881
Patzelt C, Schiltz E (1984) Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences. Proc Natl Acad Sci USA 81:5007–5011
Philippe J, Mojsov S, Drucker DJ, Habener JF (1986) Proglucagon processing in a rat islet cell line resembles phenoptype of intestine rather than pancreas. Endocrinology 119:2933–2839
Philippe J, Chick WL, Habener JF (1987) Multipotential phenotypic expression of genes encoding peptide hormones in rat insulinoma cell lines. J Clin Invest 79:351–358
Philippe J, Powers AC, Mojsov S, Drucker DJ, Comi R, Habener JF (1988) Expression of peptide hormone genes in human islet cell tumors. Diabetes 37:1647–1651
Sachs G (1974) Angewandte Statistik. Springer, Berlin Heidelberg New York
Schjoldager BTG, Mortensen PE, Christiansen J, Orskov C, Holst JJ (1989) GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in man. Dig Dis Sci 35:703–708
Shima K, Hirota M, Ohboshi C (1988) Effect of glucagon-like peptide-1 on insulin secretion. Regul Pept 22:245–252
Suzuki S, Kawai K, Mukai H, Yamashita K, (1989) Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide 1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology 125:3109–3114
Uttenthal LO, Ghiglione M, George SK, Bishop AE, Polak JM, Bloom SR (1985) Molecular forms of glucagon-like peptide 1 in human pancreas and glucagonomas. J Clin Endocrinol Metab 61:472–479
Wynick D, Williams SJ, Bloom SR (1988) Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 319:605–607
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eissele, R., Göke, R., Weichardt, U. et al. Glucagon-like peptide 1 immunoreactivity in gastroentero-pancreatic endocrine tumors: a light- and electron-microscopic study. Cell Tissue Res 276, 571–580 (1994). https://doi.org/10.1007/BF00343955
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00343955